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Abstract The availability of population-specific normative
data regarding disease severity measures is essential for
patient assessment. The goals of the current study were to
characterize the pattern of ankylosing spondylitis (AS) in
Portuguese patients and to develop reference centile charts
for BASDAI, BASFI, BASMI and mSASSS, the most
widely used assessment tools in AS. AS cases were
recruited from hospital outpatient clinics, with AS defined
according to the modified New York criteria. Demographic
and clinical data were recorded. All radiographs were
evaluated by two independent experienced readers. Centile
charts for BASDAI, BASFI, BASMI and mSASSS were
constructed for both genders, using generalized linear
models and regression models with duration of disease as
independent variable. A total of 369 patients (62.3% male,
mean±(SD) age 45.4±13.2 years, mean±(SD) disease
duration 11.4±10.5 years, 70.7% B27-positive) were
included. Family history of AS in a first-degree relative
was reported in 17.6% of the cases. Regarding clinical
disease pattern, at the time of assessment 42.3% had axial
disease, 2.4% peripheral disease, 40.9% mixed disease and
7.1% isolated enthesopatic disease. Anterior uveitis
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(33.6%) was the most common extra-articular manifesta-
tion. The centile charts suggest that females reported greater
disease activity and more functional impairment than males
but had lower BASMI and mSASSS scores. Data collected
through this study provided a demographic and clinical
profile of patients with AS in Portugal. The development of
centile charts constitutes a useful tool to assess the change
of disease pattern over time and in response to therapeutic
interventions.
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Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disorder characterized by inflammation in the spine and
sacroiliac joints leading to progressive joint ankylosis.
Peripheral joints and entheses are frequently involved, and
inflammation may involve extra-articular sites such as the
uvea, aorta, heart, lungs and kidneys. AS is a common
cause of inflammatory arthritis worldwide, with a preva-
lence of 0.2–0.9% in white European populations [1], but
its aetiology is still incompletely understood. AS typically
affects young people, with symptoms onset usually occur-
ring in the early 20s, leading to progressive deterioration of
physical function and quality of life. Work disability is
higher in AS patients than expected in the general
population, with a remarkable impact on productivity and
social costs [2], and there is some evidence of increased
mortality [3].
Assessment of disease activity and severity in AS is of
clinical utility in determining current disease status,
prognosis and the effects of therapeutic interventions. The
BASDAI [4] and BASFI [5] self-administered patient
questionnaires are the most widely used tools for the
assessment of AS activity and functional status. Metrology
is also widely used, providing an objective measure of the
effects of the disease on joint mobility; the BASMI [6] is
generally the scoring tool for AS metrology. Finally, the
mSASSS [7] scores radiographic features of AS and is now
considered the preferred method for measurement of
damage progression in patients with AS. Reference centile
charts have been developed for AS British patients for
BASDAI, BASFI and BASMI [8], but no published charts
are available from any other population. Furthermore,
reference centile charts have never been developed for
mSASSS in any studied population.
Well characterised differences between ethnic groups
regarding clinical manifestations of some other major
inflammatory conditions, such as systemic lupus erythema-
tosus [9], have been described, but there is little data about
inter-ethnic differences in AS patients. Characterising
differences between ethnic groups is an important process,
potentially guiding research into determinants of disease
manifestations and severity and being of obvious relevance
for the clinical management in the different ethnic groups
concerned.
The aim of the present study was to characterise AS
clinical manifestations in Portuguese AS patients and to
construct reference centile charts for BASDAI, BASFI,
BASMI and mSASSS in our population.
Materials and methods
We collected cross-sectional data on Portuguese AS
patients, between April 2007 and April 2008. Cases were
recruited from patients attending outpatient clinics in nine
out of 14 hospitals, which are the main rheumatology
referral centres in their regions. The hospitals involved
represent two thirds of all rheumatology centers operating
in the Portuguese Hospital National Health System (NHS).
Nationwide, the hospitals participating in our study
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accounted for approximately 75.6% of all rheumatology
visits in 2007 in Portugal. These centres were located in
seven different cities, including urban and rural zones, and
represent a broad socio-demographic spectrum of the
population treated by the NHS. The patients were selected
consecutively in each center in the 2 months prior to the
visit of the interviewers. Four previously trained rheuma-
tologists were responsible for the data collection and
physical examination of all patients enrolled in each
involved centre. This procedure facilitated a consistent data
collection and ensured a high response rate. Written
informed consent was obtained from all study participants,
and the study was approved by the Ethics Committee of the
University Hospital Centro Hospitalar de Lisboa Ocidental,
Hospital de Egas Moniz and by the Ethics Board of the
involved centres.
Data collection
All patients were selected according to the inclusion
criteria: (a) AS defined by the modified New York criteria
[10], (b) age above 18 years old, and to the exclusion
criteria: (a) other types of spondylarthritis distinct from AS.
Patients completed a questionnaire concerning demographic
characteristics, disease features and the BASDAI and
BASFI questionnaires. Age at disease onset was defined
as the age at symptom onset, and disease duration was
defined as the period of time (years) after symptoms onset.
For the evaluation of the disease status, the following
anthropometrical measures included in the Bath Ankylosing
Spondylitis Metrological Index (BASMI) were used and
performed: tragus-to-wall distance, modified Schober’s test,
lateral flexion of lumbar spine, cervical rotation and
intermalleolar distance. All patients had pelvic x-rays
performed confirming the presence of at least grade 2
bilateral, or unilateral grade 3, sacroiliitis. The modified
Stoke Ankylosing Spondylitis Severity Score (mSASSS)
[7] was determined when cervical and lumbar x-rays were
available (n=213); all radiographs were scored indepen-
dently by two of us (FS, AFM). Where there was discordance
between the scores, they were re-evaluated together by both
reviewers, and a consensus score was obtained. Laboratory
tests including ESR and HLA-B27 status, determined by
sequence-specific single-stranded oligonucleotide probes
(SSOP), were evaluated in all patients. Current treatments
including non-steroidal anti-inflammatory drugs, glucocorti-
coids, disease-modifying anti-rheumatic drugs and biological
therapies were recorded.
Statistical analysis
Descriptive statistics are presented as mean±standard
deviation when referring to quantitative variables and in
absolute frequencies and percentages when referring to
qualitative variables. The non-parametric Mann–Whitney–
Wilcoxon test was used to compare groups in the presence
of skewed data.
Centile charts, showing the 5th, 10th, 25th, 50th, 75th,
90th and 95th centiles, were estimated for males and
females separately using alternative models for mean and
standard deviation for each Bath AS indexes and mSASSS.
The centile curves were calculated using the following
equation:
centile ¼ meanþ K  SD
where K is the corresponding centile of the standard
Gaussian distribution.
The mean values were estimated by the fitting General-
ized Linear Models (GLM) for each Bath AS indexes and
mSASSS with disease duration as covariate. We tried to fit
the best model according to the data structure. We used the
Gamma, Poisson and Gaussian families and log and
identity function as link functions. The quality of adjust-
ment was assessed by the residuals analysis.
The standard deviation (SD) was estimated by linear
regression using the absolute value of the residuals from the
GLM regression multiplied by
ﬃﬃﬃﬃﬃﬃﬃﬃ
p=2
p ¼ 1:253 as the
dependent variable and the disease duration as the
independent variable.
Socio-demographic and clinical determinants of each
Bath AS index were investigated by multivariate regression
analysis using GLM. Alternative models specification was
assessed with the Akaike information criterion (AIC), the
Bayesian information criterion (BIC), deviance and Ramsey
reset test. Normality tests and residual analyses were done
to check the assumptions of models.
Coefficients with p-value <0.05 were considered signif-
icant. The statistical analysis was performed with Stata SE
10 software.
Results
Eleven outpatient clinics from seven different cities were
involved from mainland Portugal, representing a broad
spectrum of the population treated in the Hospitalar
Portuguese Health System. A total of 369 patients were
included (62.3%men and 37.1% women), with a mean age of
45.4±13.2 years (range 20–79 years). Table 1 shows the
average values of disease duration, age of symptom onset,
age of diagnosis and diagnosis delay for the whole group and
by sex. The mean disease duration was 11.4±10.5 years
(range 0–46 years), the mean age of disease onset was 26.5±
10.8 years and the mean age at diagnosis was 34.1±
12.4 years. The mean delay between onset of symptoms
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and diagnosis was 7.6±9.0 years and was less than 1 year in
51 cases (13.8%) and longer than 10 years in 86 cases
(23.3%). There was no difference in the age of symptom
onset between males and females (25.8 vs 27.5, p=0.185),
although males were diagnosed at a slightly earlier age (33.0
vs 35.8 years, p=0.040). Juvenile onset (age <16 years) was
reported in 39 (10.6%) of cases, whereas late onset (age >
40 years) was reported in 37 (10%). Family history of AS, in
a first-degree relative, was reported in 65 of 369 (17.6%)
patients.
Lower back pain (42.3%) was the most common initial
manifestation. At the time of assessment for this study,
49.9% had axial disease, 2.4% peripheral disease, 40.9%
mixed disease and 7.1% isolated enthesopatic disease.
Extra-articular manifestations were experienced by 35.2%
of the patients, with anterior uveitis (33.6%) being the most
common feature. Other associated extra-articular manifes-
tations were less frequent: psoriasis (6.2%), coexistent
inflammatory bowel disease (2.4%), pulmonary disease
(1.4%), cardiac disease (1.1%) and renal disease (0.3%).
Table 1 summarizes also data about disease activity and
its functional and structural repercussion. The patient and
physician global assessment (4.7 vs 2.6, p<0.001) differed
significantly, with physicians scoring disease severity lower
than patients. The mean value for BASDAI was 4.2±2.3,
for BASFI 4.1±2.7, for BASMI 4.0±2.5 and for mSASSS
20.9±23.1 (obtained from a sub-group of 213 patients that
had a complete radiological evaluation, including total
cervical and lumbar x-rays). Compared with men, the mean
BASDAI in women was 1.2 points higher (4.9 vs 3.7, p<
0.001) and the mean BASFI was 0.7 points higher (p=
0.010), but the mean BASMI was 0.8 points lower (p=
0.006) and the mean mSASSS was 17.6 points lower (p<
0.001). Comparing the 51 (13.8%) of patients diagnosed
with less than 1 year of diagnosis delay with the 86 (23.3%)
diagnosed with more than 10 years of diagnosis delay, no
significant differences were noted in disease duration
adjusted scores (data not shown).
In the overall cohort the mean ESR was 21.7±17.7 mm/h.
Regarding HLA B27, 290 of 360 (80.5%) were positive.
The spectrum of the different treatments that patients
received at the time of inclusion visit were also depicted.
The majority of AS cases were taking NSAIDs (79.1%),
and corticosteroids were being used by 17.6% of cases.
DMARD were being used by 48.5% of the patients; of
these cases 40.8% had only axial involvement. Sulphasa-
lazine in monotherapy was taken by 30.9% of the patients,
methotrexate in monotherapy by 8.4% and 6% were taking
both. TNF-blockade was being used by 22% of the patients
of whom 40.7% had only axial disease. Multiple linear
regression analysis revealed a statistically significant higher
[1.5 (95% CI: 0.2; 2.8)] BASMI score in patients taking
anti-TNF-α therapy (model not shown) as compared to the
remaining patients.
Centile charts were developed from a final study
population comprising 326 patients for BASDAI, 323
patients for BASFI, 301 for BASMI and 206 for mSASSS.
Centile charts were constructed for both genders, showing
the 5th, 10th, 25th, 50th, 75th, 90th and 95th centiles
(Fig. 1). Our cross-sectional study shows that BASFI,
Table 1 Characteristics of the
overall cohort and analysis
by gender
Mean ± standard deviation
*Mann–Whitney–Wilcoxon test
ªt-test comparison between
patient and medical
evaluation
Total Male Female p-value*
Gender (n;(%)) 369 (100%) 232 (62.8%) (137) 37.1% –
Age (years) 45.4±13.2 45.7±13.5 44.9±13.9 0.52
Age at onset (years) 26.5±10.8 25.8±10.8 27.5±10.8 0.185
Age at diagnosis (years) 34.1±13.4 33.0±12.3 35.8±12.4 0.040
Time of evolution (years) 18.9±12.7 19.8±12.6 17.6±13.0 0.068
Disease duration (years) 11.4±10.5 12.6±11.0 9.5±9.3 0.022
Diagnosis delay (years) 7.6±9.0 7.1±9.0 8.3±9.0 0.081
Patient global assessment(cm) 4.7±2.4 4.3±2.5 4.8±2.3 0.072
Physician global assessment (cm) 2.6±1.9 2.5±1.9 2.6±1.8 0.36
<0.001ª
BASDAI 4.2±2.3 3.7±2.2 4.9±2.3 <0.001
BASFI 4.1±2.7 3.8±2.6 4.5±2.7 0.010
BASMI 4.0±2.5 4.3±2.6 3.5±2.2 0.006
mSASSS 20.9±23.1 27.4±24.6 9.8±14.7 <0.001
ESR (mm/h) 21.7±17.7 20.1±17.4 24.3±18.2 0.012
HLA-B27 positivity
(n positive: n total, (%))
290:360 (80.5%) 183:220 (83.2%) 107:140 (76.4%) –
Fig. 1 BASDAI, BASFI, BASMI and mSASSS reference centile charts
for both genders, showing the 5th, 10th, 25th, 50th, 75th, 90th and 95th
centiles
b
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BASMI and mSASSS scores continue to increase as a
function of disease duration, even after >20 years, in both
males and females. By contrast, disease activity assessed by
BASDAI did not change over time.
Comparison of AS between genders
As in other populations, in this study AS affected more
frequently males than females. The average age, age at
symptom onset and the diagnostic delay were similar in
both genders. Females reported greater disease activity
(BASDAI) and functional impairment (BASFI) but had
better metrology (BASMI) and better radiological evalua-
tion (mSASSS). These differences were valid for the results
as a whole but also when different periods of disease
duration were evaluated.
Discussion
We report here the first characterization of a Portuguese cohort
of AS patients. This study describes the socio-demographic,
clinical, radiological and biological profile of AS in our
country. Furthermore, we have developed reference centile
charts for indices of disease activity, function, metrology and
mSASSS in our population. This study involved patients
recruited from hospital outpatient clinics, a patient population
likely to have more severe disease than the overall AS
population. Therefore, our centile charts will need to be
assessed in a community-recruited AS case cohort before they
can be used in non-hospital based settings.
This study confirms that AS in Portugal have similar
characteristics to the disease pattern described in other
European populations. There is a striking male predomi-
nance (62.3% males vs 37.1% females), and the age at
symptom onset (26.5±10.8 years) and the frequency of
extra-articular features were similar to those reported in
previous Portuguese studies [11, 12] or in other studies of
white European ethnic groups [13, 14].
Diagnostic delay in this cohort was similar to that
reported in other developed countries (7.6±9.0 years) [13–
19]. An early diagnosis (less than 1 year after starting
symptoms) was established in only 13.8% of the cases.
There are many potential explanations for this, but one
of the contributors is likely to be the low sensitivity of
the New York classification criteria when used in the
clinical practice. It will be interesting to observe
whether diagnostic delay is reduced with the daily use
of the Assessment of SpondyloArthritis international
Society (ASAS) undifferentiated spondylarthritis criteria
[20]. Interestingly, no statistical difference was found
between patients with an early and late diagnosis regard-
ing disease activity, function, metrology and radiological
repercussion. This observational data suggests that early
diagnosis may not confer a better prognosis. These results
must be interpreted in the light of the cross-sectional,
observational study design. It may be that early diagnosis
is associated with more active disease, reducing the
potential benefit of an early intervention rather than
simply reflecting paucity of benefit of early treatment.
On the other hand, many patients in this cohort were
diagnosed as AS cases more than 10 years ago, when
therapeutic strategies were clearly different from the ones
that are available now.
In terms of therapeutic approach there are some
interesting data for analysis. As usual a great proportion
of patients are taking NSAIDs (79.1% daily or on demand).
A lower but significant proportion of cases (17.6% in total
and 12.5% in axial form) are taking corticosteroids. These
results reinforce previous results from a preliminary study
in Portuguese SPA [11] where corticosteroid prescription
was considered higher than in other countries. Sulphasala-
zine is the most used DMARD (36.9%). TNF-α blockade
(22%) is prescribed in a relatively small group of patients as
in other studied populations [14, 21] and is used much less
often than the estimated proportion of cases thought by
expert opinion to warrant treatment with this specific
therapy (30–49%) [22, 23]. The positive correlation
between BASMI and anti-TNF-α therapy (p=0.024) may
be an indirect evidence of the delay in starting biologic
therapies in this cohort.
The mean BASDAI (4.2±2.3), BASFI (4.1±2.7) and
BASMI (4.0±2.5) values were similar to values of other
published cohorts [13, 21, 24].
Reference centile charts have been developed in British
AS patients for BASDAI, BASFI and BASMI [8], but no
published charts are available from any other population.
Furthermore, there is little data about inter-ethnic differ-
ences in AS characteristics, and no reference centile charts
have been published for mSASSS in any studied popula-
tion. In constructing centile charts we tried different
generalized linear models and selected the generalized
linear model with Gaussian family distribution and identity
link function (this is linear regression model) for the Bath
AS indices and selected the generalized linear model with
Gamma family distribution and log link function for
mSASSS. In spite of using different statistical methodolo-
gies, the smaller sample size available to us and the
differences in gender distribution between the two studies,
our findings are very similar to those reported previously
for the British population [8].
The charts do provide some descriptive information
regarding disease activity, functional impairment, metrolo-
gy and radiological impact in AS over time. These
reference charts (Fig. 1), after proper validation, may be
applied to compare the same population over time or
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different populations. This visual representation may also
improve patient understanding of the disease, which may
improve patient compliance to treatment. Other potential
benefits as their application on an individual basis would
require the collection of longitudinal data and trials to
confirm them. A potential weakness of the study is that the
data is cross-sectional, and it is not yet known to what
extent disease activity measures in individual patients track
consistently relative to the overall patient cohort. Thus,
longitudinal studies are required to determine if patients
with high or low outcome measures at one point in time
remain consistently high or low at other time points. The
patient selection method is another potential limitation of
the study, possibly affecting the extent to which the data
reflects cases with AS overall in the general population,
which may be milder than the clinical cohort studied here.
However, as most AS patients in Portugal receive their care
through outpatient clinics such as those studied here and in
this study a high proportion of those clinics covering a
range of demographic regions were included, we feel that
this bias is likely to be minor.
Nonetheless, the analyses of BASDAI charts (Fig. 1)
confirm the previous finding that AS remains active
throughout the disease course [25]. Furthermore, as
previously reported in English patients, women are more
functionally impaired than men and have greater disease
activity despite better metrology and, in our cohort, less
radiological change. These results suggest once again
differences between men and women in the AS phenotypic
expression.
In conclusion, we have described the clinical profile of
AS in Portugal, and simultaneously we have constructed
the centile charts for BASDAI, BASFI, BASMI and
mSASSS. A potential use of these charts is to show
changes in the clinical profile of AS patients in Portugal
over time due to either changes in treatment strategies or
changes in the disease itself. An additional interest would
be to facilitate comparisons between different populations.
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